8 research outputs found
Prostatakarzinomfrüherkennung in Deutschland: Untersuchung einer repräsentativen Bevölkerungsstichprobe
In der vorliegenden Analyse werden Einflussfaktoren
auf die Inanspruchnahme der Prostatakarzinomfrüherkennung
(Prostata-KFU) in Deutschland untersucht. Eine repräsentative Stichprobe von 10.659 Männern im Alter
von 45–70 (Mittel = 55,2) Jahren wurde
nach ihrer Prostata-KFU-Inanspruchnahme
befragt. Dabei wurden soziodemographische
Faktoren (Alter, familiärer Status, Einkommen,
Bildung, Krankenkassenstatus), familiäre
Krebsbelastung, Einfluss einer ärztlichen
Empfehlung, sowie Teilnahme an einer allgemeinen
Gesundheitsuntersuchung („Checkup
35“) erfasst.
Zwei Drittel der Stichprobe gibt an, mindestens
einmal eine DRU erhalten zu haben,
knapp die Hälfte der Männer (48%) hat bereits
einen PSA-Test durchführen lassen. Die
Anzahl der Männer, die regelmäßig an einer Prostata-KFU teilnehmen, ist deutlich geringer
(44% DRU, 33% PSA). Die Inanspruchnahme
der Prostata-KFU steigt mit dem Alter an,
dagegen haben sozioökonomische Variablen
wie Bildung fast keinen Einfluss. Eine familiäre
Krebsbelastung erhöht die Wahrscheinlichkeit,
an einer Prostata-KFU teilzunehmen.
Die Regelmäßigkeit der Teilnahme bleibt davon
unbeeinflusst. Die wichtigsten Prädiktoren
der (regelmäßigen) Inanspruchnahme
sind Arztempfehlung und Teilnahme an einer
allgemeinen Gesundheitsuntersuchung
(„Checkup 35“)
Gastroenteropancreatic Neuroendocrine Tumors: Standardizing Therapy Monitoring with Ga-DOTATOC PET/CT Using the Example of Somatostatin Receptor Radionuclide Therapy
The purpose of this study was to standardize therapy monitoring of hepatic metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the course of somatostatin receptor radionuclide therapy (SRRT). In 21 consecutive patients with nonresectable hepatic metastases of GEP-NETs, chromogranin A (CgA) and 68 Ga-DOTATOC PET/CT were compared before and after the last SRRT. On 68 Ga-DOTATOC PET/CT, the maximum standard uptake values (SUV max ) of normal liver and hepatic metastases were calculated. In addition, the volumes of hepatic metastases (volume of interest [VOI]) were measured using four cut-offs to separate normal liver tissue from metastases (SUV max of the normal liver plus 10% [VOI liver+10% ], 20% [VOI liver+20% ], 30% [VOI liver+30% ] and SUV = 10 [VOI 10SUV ]). The SUV max of the normal liver was below 10 (7.2 ± 1.3) in all patients and without significant changes. Overall therapy changes (Δ) per patient (mean [95% CI]) were statistically significant with p < .01 for ΔCgA = −43 (−69 to −17), ΔSUV max = −22 (−29 to −14), and ΔVOI 10SUV = −53 (−68 to −38)% and significant with p < .05 for ΔVOI liver+10% = −29 (−55 to −3)%, ΔVOI liver+20% = −32 (−62 to −2) and ΔVOI liver+30% = −37 (−66 to −8). Correlations were found only between ΔCgA and ΔVOI 10SUV ( r = .595; p < .01), ΔSUV max and ΔVOI 10SUV (0.629, p < .01), and SUV max and ΔSUV max ( r = .446; p < .05). 68 Ga-DOTATOC PET/CT allows volumetric therapy monitoring via an SUV-based cut-off separating hepatic metastases from normal liver tissue (10 SUV recommended)
Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases
In a technical development study approved by the institutional ethics committee, the feasibility of fast diffusion-weighted imaging as a replacement for conventional magnetic resonance (MR) imaging sequences (short inversion time inversion recovery [STIR] and T1-weighted spin echo [SE]) and positron emission tomography (PET)/computed tomography (CT) in the detection of skeletal metastases from prostate cancer was evaluated. MR imaging and carbon 11 ((11)C) choline PET/CT data from 11 consecutive prostate cancer patients with bone metastases were analyzed. Diffusion-weighted imaging appears to be equal, if not superior, to STIR and T1-weighted SE sequences and equally as effective as (11)C-choline PET/CT in detection of bone metastases in these patients. Diffusion-weighted imaging should be considered for further evaluation and comparisons with PET/CT for comprehensive whole-body staging and restaging in prostate and other cancers